Equillium (EQ) Operating Income (2018 - 2026)
Equillium (EQ) posted quarterly Operating Income of -$5.6 million for Q1 2026, up 36.75% year-over-year from -$4.1 million in Q1 2025, and down 41.6% quarter-over-quarter from -$4.0 million in Q4 2025.
Equillium (EQ) Operating Income (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Operating Income for 9 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 36.75% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at -$20.4 million (down 42.02% YoY), while the FY2025 annual figure was -$23.6 million, down 185.81% from the prior year.
- Operating Income slipped to -$5.6 million in Q1 2026 per EQ's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Operating Income topped out at $2.0 million in Q4 2022 and bottomed at -$37.3 million in Q1 2022.
- Historically, Operating Income has averaged -$6.7 million across 5 years, with a median of -$4.1 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income surged 119.66% — and 2025, when it tumbled 6128.0%.
- Equillium's Operating Income stood at $2.0 million in 2022, then plunged by 256.71% to -$3.2 million in 2023, then slumped by 46.81% to -$4.7 million in 2024, then gained by 15.67% to -$4.0 million in 2025, then sank by 41.6% to -$5.6 million in 2026.
- Business Quant data shows EQ's Operating Income at -$5.6 million in Q1 2026, -$4.0 million in Q4 2025, and -$4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | -5.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.16 Mn |
| Mar 31, 2026 | -5.61 Mn |
| Dec 31, 2025 | -3.96 Mn |
| Sep 30, 2025 | -4.58 Mn |
| Jun 30, 2025 | -6.23 Mn |
| Mar 31, 2025 | -8.87 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Sep 30, 2024 | -679,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Mar 31, 2024 | -2.79 Mn |
| Dec 31, 2023 | -3.20 Mn |
| Sep 30, 2023 | -3.62 Mn |
| Jun 30, 2023 | -3.59 Mn |
| Mar 31, 2023 | -4.11 Mn |
| Dec 31, 2022 | 2.04 Mn |
| Sep 30, 2022 | -13.24 Mn |
| Jun 30, 2022 | -13.55 Mn |
| Mar 31, 2022 | -37.33 Mn |
| Dec 31, 2021 | -10.39 Mn |
| Sep 30, 2021 | -9.86 Mn |